Skip to main content
Premium Trial:

Request an Annual Quote

This Would've Been a Much Less Pleasant Topic in 2003

LinkedIn has a conversation going about whether bioinformatics is still a viable career. There are several good responses to the question, most of which take a positive view, saying that the field will only increase in value in the coming years. Over at his Microarray Blog, Albin Paul adds to the discussion. He writes, "Though bioinformatics companies have lost the sheen, the growing need for data analysis is unmistakable, with more large genome projects being announced everyday."


The Scan

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.